Assessment of the efficacy of Dupilumab in the treatment of Atopic Dermatitis in adults: an integrative review from 2019 to 2023
DOI:
https://doi.org/10.55892/jrg.v8i18.1797Keywords:
Dermatite Atópica, Dupilumabe, Eficácia, Tratamento, AdultosAbstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects both adults and children, with significant impacts on quality of life. In cases of moderate to severe AD in adults, conventional treatments are often insufficient for effective symptom control. In this context, dupilumab, a recently approved biologic for the management of AD, has emerged as a promising therapeutic alternative. The aim of this research is to evaluate the efficacy of dupilumab in the treatment of AD in adults. This study is an integrative literature review. Research was conducted through the analysis of 16 articles published between 2019 and 2023, selected from the LILACS, PUBMED, and SCIELO databases, based on the guiding question: "What is the efficacy of dupilumab in the treatment of atopic dermatitis in adults?". Articles published in Portuguese and/or English were selected, organized, and systematized using a flow diagram. The results indicated that dupilumab was effective in reducing AD symptoms, such as pruritus and skin lesions, with a significant improvement in EASI and SCORAD scores. Efficacy was observed both as monotherapy and in combination with topical treatments, with more pronounced effects in a biweekly administration regimen. The treatment was well tolerated, with adverse reactions such as conjunctivitis and upper respiratory infections generally being mild and manageable. The analysis showed that frequent administration regimens sustain the therapeutic benefits over time. It is concluded that dupilumab is an effective and safe option for the treatment of AD in adults, offering an alternative to fill a therapeutic gap in the management of the disease, providing prolonged efficacy that was not achieved with previous treatments.
Downloads
References
ANTUNES, A. et al. Guia prático de atualização em dermatite atópica - Parte I: etiopatogenia, clínica e diagnóstico. Posicionamento conjunto da Associação Brasileira de Alergia e Imunologia e da Sociedade Brasileira de Pediatria. Arq Asma Alerg Imunol., v. 1, n. 04, p. 149, 2017.
AOKI, V. et al. Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology. An. Bras. Dermatol., v. 94, n. 2, p. 67-75, 2019.
BECK, L. et al. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. [S.I.], v. 23, n. 2, p. 393-408, mai. 2022.
BLAUVELT, A. et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. Journal of the American Academy of Dermatology, [S.I.], v. 80, n. 1, p. 158-167, jan. 2019.
BOSMA, A. et al. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol., [S.I.], v. 83, n. 5, p. 1275-1384, nov. 2020.
DELEURAN, M. et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol., [S.I.], v. 82, n. 2, p. 377-388, fev. 2020.
FARGNOLI, M. et al. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. The Journal of dermatological treatment, [S.I.], v. 33, n. 2, p. 1146-1149, mar. 2022.
GIAVINA-BIANCHI, M. Manejo dos eventos adversos do dupilumabe na dermatite atópica e no prurigo nodular. Arq Asma Alerg Imunol, [S.I.], v. 8, n. 1, p. 14-20, 2024.
GRIGORIO, M. et al. Dermatitis atópica grave y su difícil manejo clínico. Contribuciones a Las Ciencias Sociales, São José dos Pinhais, v.17, n.7, p. 01-08, jun. 2024.
GORI, N. et al. Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study. J Dermatolog Treat., [S.I.], v. 34, n. 1, p. 2230685, dez. 2023.
GUILLEN, J. et al. Abordagens no tratamento da dermatite atópica. BWS Journal, [S. l.], v. 4, p. 1–18, 2021. Disponível em: https://bwsjournal.emnuvens.com.br/bwsj/article/view/224. Acesso em: 16 setembro 2024.
GUTTMAN-YASSKY, E. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol., [S.I.], v. 143, n. 1, p. 155-172, set. 2019.
KAMAL, M. et al. Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis. Clin Transl Sci.,[S.I.], v. 15, n. 10, p. 2342-2354, out. 2022.
LIMA, E; ANDRADE, L. Atenção farmacêutica no tratamento de doenças de pele: Dermatite Atópica. Revista Ibero- Americana de Humanidades, Ciências e Educação, São Paulo, v. 9, n. 11, p. 1065-1078, nov. 2023.
LUQUETTI, C. et al. Dermatite atópica (eczema): patogênese, manifestações clínicas e diagnóstico. Brazilian Journal of Implantology and Health Sciences, [S.I.], v. 6, n. 7, p. 3193-3205, jul. 2024.
MARTÍNEZ-DOMÉNECH, A. et al. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience. Actas Dermo-Sifiliográficas, [S.I.], v. 115, n. 2, p. 150-158, fev. 2024.
MEROLA, J. et al. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study. Br J Dermatol., [S.I.], v. 189, n. 6, p. 685-694, nov. 2023.
MILANESI, N. et al. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis. Italian journal of dermatology and venereology, [S.I.], v. 157, n. 2, p. 142-145, abr. 2022.
MONTEIRO, D; PINHO, L. Síndrome da retirada de corticoides tópicos em pacientes com dermatite atópica: Revisão de literatura. Monografia, trabalho de conclusão de curso, curso de Farmácia, Centro Universitário FAMETRO, Fortaleza, 2023.
NAGATO, A; PERILLO, V. O impacto psicológico, social e econômico da dermatite atópica no Brasil. Monografia, trabalho de conclusão de curso, curso de Medicina, Universidade Católica de Goiás (PUC GO), Goiânia, 2023.
NAKAHARA, T. et al. Efficacy of Dupilumab for Atopic Dermatitis According to Clinical Course and Clinical Findings: A Multicentre Retrospective Study. Acta Derm Venereol., [S.I.], v. 101, n. 11. p. adv00586, nov. 2021. DOI: 10.2340/actadv.v101.369.
NAZZARI, E; ASSONI, A. Dupilumabe como alternativa de tratamento na dermatite atópica moderada a grave: estudo de caso. Revista Perspectiva, [S. l.], v. 48, n. 7, p. 7-16, jun. 2024.
NETTIS, E. et al. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study. Journal of investigational allergology & clinical immunology, [S.I.], v. 32, n. 2, p. 124-132, abr. 2022.
PEREYRA-RODRIGUEZ J. et al. 104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain. An Bras Dermatol., [S. l.], v. 96, n. 6, p. 787-790, dez. 2021.
QUADROS, B. et al. Dermatite Atópica: Perspectivas Atuais em Diagnóstico, Manejo Terapêutico, Controle de Recorrências e Prevenção de Complicações. A.R International Health Beacon Journal, [S. l.], v. 1, n. 4, p. 341–352, 2024. Disponível em: https://healthbeaconjournal.com/index.php/ihbj/article/view/55. Acesso em: 15 set. 2024.
RUIZ-VILLAVERDE, R. et al. The Safety of Dupilumab in Clinical Practice: 52 Weeks of Experience at 5 Referral Hospitals in Andalusia. Actas dermo-sifiliograficas, [S.I.], v. 111, n. 8, p. 699-700, out. 2020.
WORM, M. et al. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol., [S. l.], v. 156, n. 2, p. 131-143, fev. 2020.
ZHANG, J. et al. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry. J Am Acad Dermatol., , v. 91, n. 2, p. 300-311, abr. 2024.
ZHAO, Y. et al. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol., v. 186, n. 4, p. 633-641, abr. 2022.
